Alyeska Investment Group, L.P. Bio Line Rx Ltd. Transaction History
Alyeska Investment Group, L.P.
- $16.5 Billion
- Q2 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,953,366 shares of BLRX stock, worth $820,413. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,953,366Holding current value
$820,413% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
38Shares Held
4.34MCall Options Held
49.9KPut Options Held
122K-
Cvi Holdings, LLC Wilmington, DE816KShares$342,5864.05% of portfolio
-
Envestnet Asset Management Inc214KShares$89,8090.0% of portfolio
-
Values First Advisors, Inc.198KShares$82,9560.06% of portfolio
-
Atria Investments LLC Charlotte, NC134KShares$56,2690.0% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$51,9030.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $25.8M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...